Additional file 1 of Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Additional file 1: Table S1. A list of tyrosine kinase inhibitors used in this study. Table S2. A list of antibodies used in this study. Table S3. Results of drug screening other than tyrosine kinase inhibitors. Table S4. Type II MET-TKIs evaluated in this study. Table S5. Clinical information of two phase I studies of foretinib. Table S6. Clinical information of five phase II studies of foretinib.